Interlaboratory comparison of endotoxin contamination assessment of nanomaterials

Other authors

Institut Català de la Salut

[Hannon G] Nanomedicine and Molecular Imaging Group, Department of Clinical Medicine, Trinity Translational Medicine Institute, Trinity College Dublin, Dublin, Ireland. Laboratory of Biological Characterization of Advanced Materials (LBCAM), Trinity Translational Medicine Institute, Trinity College Dublin, Dublin, Ireland. [Heaton BJ, Plant-Hately A, David C, Liptrott NJ] Immunocompatibility Group, Department of Pharmacology and Therapeutics, Institute of Systems, Molecular, and Integrative Biology, University of Liverpool, Liverpool, UK. Centre of Excellence for Long-Acting Therapeutics, Department of Pharmacology and Therapeutics, Institute of Systems, Molecular, and Integrative Biology, University of Liverpool, Liverpool, UK. [Egizabal A] TECNALIA, Basque Research and Technology Alliance (BRTA), Donostia-San Sebastián, Spain. [Abasolo I] Grup de Bioquímica Clínica, Vehiculització de Fàrmacs i Teràpia, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Networking Research Centre for Bioengineering, Biomaterials, and nanomedicine (CIBER-BBN), Instituto de Salud Carlos III, Madrid, Spain. Validació Funcional i Investigació Preclínica, Vall d’Hebron Institut de Recerca (VHIR), Universitat Autònoma de Barcelona, Bellaterra, Spain. [Andrade F] Grup de Bioquímica Clínica, Vehiculització de Fàrmacs i Teràpia, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Networking Research Centre for Bioengineering, Biomaterials, and nanomedicine (CIBER-BBN), Instituto de Salud Carlos III, Madrid, Spain

Vall d'Hebron Barcelona Hospital Campus

Publication date

2024-12-16T09:12:47Z

2024-12-16T09:12:47Z

2024-10-24



Abstract

Assessment; Endotoxin; Nanomaterials


Evaluación; Endotoxinas; Nanomateriales


Avaluació; Endotoxines; Nanomaterials


Endotoxin contamination is a significant hurdle to the translation of nanomaterials for biomedical applications. Multiple reports now describe that more than one-third of nanomaterials fail early pre-clinical assessment due to levels of endotoxin above regulatory requirements. Additionally, most immunological studies or in vivo studies testing nanomaterials in the literature lack inclusion of this assessment, which may lead to false-positive or false-negative results if high levels of the contaminant are present. The currently approved methods for endotoxin contamination assessment rely on enzymatic activity and wavelength absorbance as their endpoint, and many nanomaterials can interfere with such assays. For this reason, we devised an interlaboratory comparison of endotoxin contamination assessment for a range of nanomaterials to challenge the current international organization for standardization and pharmacopeia standards. Herein, we show that detected endotoxin levels could vary considerably between groups, and, in some instances, nanomaterials could both pass and fail regulatory endotoxin limits for medical devices depending on the group undertaking the assessment, all while passing all quality criteria standards. This work emphasises the requirement for multiple assays to fully assess the endotoxin levels in a nanomaterial and highlights the need for additional assays to be developed in this space.


This work was funded by the European Commission's Horizon 2020 research and innovation programme (grant agreement: 814607).

Document Type

Article


Published version

Language

English

Publisher

Royal Society of Chemistry

Related items

Nanoscale;16(45)

https://doi.org/10.1039/d4nr02821j

info:eu-repo/grantAgreement/EC/H2020/814607

Recommended citation

This citation was generated automatically.

Rights

Attribution 4.0 International

http://creativecommons.org/licenses/by/4.0/

This item appears in the following Collection(s)